Rishi Gupta - Oct 16, 2023 Form 4 Insider Report for Turnstone Biologics Corp. (TSBX)

Role: Director, 10%+ Owner
Signature: /s/ P. Joseph Campisi, Jr., Attorney-in-Fact
Stock symbol: TSBX
Transactions as of: Oct 16, 2023
Transactions value $: $0
Form type: 4
Date filed: 10/17/2023, 06:40 PM
Previous filing: Jul 24, 2023
Next filing: Feb 15, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TSBX	Stock Option (Right to Buy)	Award	$0	+25.5K		$0.00	25.5K	Oct 16, 2023	Common Stock	25.5K	$2.61	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Thirty three and thirty three one hundreds percent (33.33%) (and thirty three and thirty four one hundreds percent (33.34%) for year three) of the shares subject to the option will vest in three (3) annual installments commencing on the date of the first annual general meeting of stockholders occurring after October 12, 2023, subject to the Reporting Person's continuous service through each such vesting date.
F2	Pursuant to an agreement between OrbiMed Advisors LLC and OrbiMed Capital GP VI LLC, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefits thereof, to OrbiMed Advisors LLC and OrbiMed Capital GP VI LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments VI, LP.

Content

Thirty three and thirty three one hundreds percent (33.33%) (and thirty three and thirty four one hundreds percent (33.34%) for year three) of the shares subject to the option will vest in three (3) annual installments commencing on the date of the first annual general meeting of stockholders occurring after October 12, 2023, subject to the Reporting Person's continuous service through each such vesting date.

Pursuant to an agreement between OrbiMed Advisors LLC and OrbiMed Capital GP VI LLC, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefits thereof, to OrbiMed Advisors LLC and OrbiMed Capital GP VI LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments VI, LP.